BeyondSpring wins Fast Track for plinabulin in post-ICI NSCLC

BeyondSpring has secured FDA Fast Track designation for plinabulin combined with docetaxel in patients with advanced or metastatic non-squamous non-small cell lung cancer who lack actionable genomic alterations and whose disease has progressed after both anti-PD-(L)1 therapy and platinum-based chemotherapy. The designation covers the second- and third-line patient population that is the focus of the company's global Phase 3 DUBLIN-4 trial.

Simultaneously, the NASDAQ-listed company announced a structural financing transaction under which it will sell its majority equity interest in its Chinese subsidiary, Dalian Wanchunbulin Pharmaceuticals, to Biolin Investment Limited. In return, Biolin will fund clinical development activity in China, expected to account for around 221 of the trial's planned 442 patients. BeyondSpring retains global rights to plinabulin outside Greater China and will receive access to the China-generated clinical data for its integrated registration dataset.

Clinical rationale and data package

Plinabulin is described by the company as a first-in-class GEF-H1 agonist whose proposed mechanism encompasses dendritic cell maturation, anti-angiogenic activity and mitigation of chemotherapy-induced neutropenia. The clinical case for DUBLIN-4 rests primarily on data from the Phase 3 DUBLIN-3 trial, published in The Lancet Respiratory Medicine in 2024. That 559-patient study showed a statistically significant overall survival benefit for the plinabulin-plus-docetaxel combination over docetaxel alone in EGFR wild-type NSCLC. Within the non-squamous subgroup of 332 patients, the OS hazard ratio was 0.72 (p=0.0078). A post hoc analysis of the DUBLIN-3 post-ICI subgroup produced a median OS of 15.8 months with the combination versus 11.7 months with docetaxel alone, with an HR of 0.55.

Prospective support came from Phase 2 Study 303 (n=47), presented at ASCO 2026, in which plinabulin combined with docetaxel and a PD-1 inhibitor produced a median PFS of 7.0 months, a disease control rate of 79.5%, a confirmed objective response rate of 18.2%, and a two-year OS rate of 58% in patients who had progressed on prior PD-1 inhibition. BeyondSpring notes that this two-year OS rate is approximately double the historical figure reported with docetaxel in a comparable population, though post hoc and single-arm data of this kind carry interpretive caveats.

Chief executive Min Qiu said the Fast Track designation "underscores the significant unmet medical need" in the post-ICI non-squamous NSCLC setting, where docetaxel remains the standard of care and 12 Phase 3 trials testing alternative regimens, including four antibody-drug conjugate programmes, have failed to demonstrate an OS advantage over docetaxel.

Market context and competitive landscape

The post-ICI second-line NSCLC space is one of the most actively contested in oncology, and the sequential failure of ADC approaches has sustained interest in mechanistically differentiated combinations. BeyondSpring's framing of plinabulin as an immune resensitiser sits alongside broader industry efforts to convert checkpoint-refractory tumours, including bispecific antibody programmes and tumour-infiltrating lymphocyte approaches from several clinical-stage companies.

The China partnership structure reduces BeyondSpring's cash obligations for DUBLIN-4 without issuing new equity, which the company characterises as capital-efficient. Regulatory read-across of China-generated data into ex-China submissions remains a live question under evolving FDA guidance on global multiregional trials, and investors will need to assess how integrated that dataset can be for any eventual NDA filing.

DUBLIN-4's next formal inflection point is a prespecified interim analysis at 221 progression-free survival events. The pace of that readout will depend substantially on China enrolment under the Biolin arrangement, making execution risk there a key variable to monitor.